IBEX 35
11.106,30 +74,00 (+0,67%) Euro Stoxx 50
4.945,45 +38,15 (+0,78%) Dólar/Euro
1,0733 +0,0036 (+0,33%) Petróleo Brent
85,60 +0,36 (+0,42%) Oro
2.339,10 +7,90 (+0,34%) Bitcoin EUR
56.973,76 -2.924,75 (-4,88%)
DMK Pharmaceuticals Corporation (DMKPQ)
DMK Pharmaceuticals Corporation
11682 El Camino Real
Suite 300
San Diego, CA 92130
United States
858 997 2400
https://www.dmkpharmaceuticals.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 11
Descripción
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Gobierno corporativo
El ISS Governance QualityScore de DMK Pharmaceuticals Corporation, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
